Physician profile
Jayson Tripp
NPI 1578053138
$12,612.23
in general payments reported to CMS, 2019-2025
27 companies · $4,030 in 2025
The $4,030 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $70.42 · 2021: $430 · 2022: $1,345 · 2023: $3,125 · 2024: $3,612 · 2025: $4,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $22.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,744.74 |
| Education | $22.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,855.60 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,390.71 | 2021-2025 | Caplyta |
| Corium, LLC | $1,265.87 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $1,170.44 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,131.09 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $1,084.89 | 2022-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $591.91 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $504.98 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $494.77 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $408.19 | 2022-2025 | Trintellix |
| Tris Pharma INC | $403.95 | 2022-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $382.73 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $310.35 | 2021-2025 | Ingrezza |
| Almatica Pharma LLC | $282.92 | 2022-2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $267.49 | 2024-2025 | Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $232.69 | 2023 | Quviviq |
| Biogen, INC. | $172.72 | 2020-2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $148.39 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $114.04 | 2022-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $90.10 | 2022-2023 | Spravato |
| Acadia Pharmaceuticals INC | $81.09 | 2021 | |
| Noven Therapeutics, LLC | $67.93 | 2024 | Secuado, Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $48.71 | 2025 | Cobenfy |
| Harmony Biosciences LLC | $47.37 | 2024-2025 | |
| Vertical Pharmaceuticals, LLC | $29.38 | 2024-2025 | Relexxii |
| Merck Sharp & Dohme LLC | $18.56 | 2022 | |
| Neos Therapeutics, LP | $15.36 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Tripp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.